Pilot trials of oral betaine in participants with metabolic dysfunction-associated steatotic liver disease and elevated alanine aminotransferase
Betaine 8, 4, and 2 g/day for 12-24 weeks significantly reduced ALT and other serologic markers of liver injury among participants with clinically defined MASLD and an elevated ALT.
Authors
- Andrew Lim (ORCID: https://orcid.org/0000-0003-2179-1553)
- Alejandro E. Mayorca‐Guiliani (ORCID: https://orcid.org/0000-0001-8137-4722)
- Alejandro Montilla (ORCID: https://orcid.org/0000-0003-0491-3360)
- Olga Malysheva (ORCID: https://orcid.org/0000-0002-8626-5071)
- Sabrina Cruz (ORCID: https://orcid.org/0000-0003-1945-1672)
- Diana Julie Leeming (ORCID: https://orcid.org/0000-0002-4256-140X)
- M.A. Karsdal (ORCID: https://orcid.org/0000-0001-5026-8740)
- Md. Ashraf Uddin (ORCID: https://orcid.org/0000-0002-4316-4975)
- Marie A. Caudill (ORCID: https://orcid.org/0000-0002-7192-5743)
- Timothy R. Morgan (ORCID: https://orcid.org/0000-0003-1328-0307)
- Cristina Alonso (ORCID: https://orcid.org/0000-0002-2019-678X)
- Craig J. McClain (ORCID: https://orcid.org/0000-0002-7219-8939)
- Frederik Høbjerg Svejsø
Institutions
- University of Copenhagen (DK)
- University of Louisville (US)
- University of California, Irvine (US)
- Cornell University (US)
- Euskadiko Parke Teknologikoa (ES)
- Riverside Community Hospital (US)
- Louisville VA Medical Center (US)
- Nordic Bioscience (Denmark) (DK)
- VA Long Beach Healthcare System (US)
Publication Details
- Journal
- Hepatology
- Published
- 2025-08-04
- DOI
- https://doi.org/10.1097/hep.0000000000001477
- Citations
- 4
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.42